본문 바로가기

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
HAEMATOLOGICA103(12) · pp.2079 · 2018
피인용
Web of Science 232Scopus 248
FWCI (Scopus)
10.29
JCR IF
JCR 2017 9.09
ISSN
0390-6078

저자

  1. Spencer, Andrew제1저자교신저자Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia
  2. Lentzsch, SuzanneDivision of Hematology/Oncology, Columbia University, New York, United States
  3. Weisel, KatjaUniversitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tübingen, Germany
  4. Avet-Loiseau, HervéUnite de Genomique du Myelome, CHU Rangueil, Toulouse, France
  5. Mark, Tomer M.Department of Medicine, University of Colorado, Aurora, United States
  6. Spicka, IvanClinical Department of Haematology, 1st Medical Department, Charles University in Prague, Czech Republic
  7. Masszi, TamasDepartment of Haematology and Stem Cell Transplantation, St László Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
  8. Lauri, BirgittaDepartment of Hematology, Sunderbyn Hospital, Luleå, Sweden
  9. Levin, Mark-DavidAlbert Schweitzer Hospital Department of Internal Medicine, Dordrecht, Netherlands
  10. Bosi, AlbertoDepartment of Hematology, Careggi Hospital and University of Florence, Italy
  11. Hungria, VaniaIrmandade Da Santa Casa De Misericordia De São Paulo, Brazil
  12. Cavo, Michele“Seràgnoli” Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy
  13. Lee, Je-JungDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea
  14. Nooka, Ajay K.Winship Cancer Institute, Emory University, Atlanta, United States
  15. Quach, HangSt. Vincent's Hospital, University of Melbourne, Australia
  16. Lee, CindyRoyal Adelaide Hospital, Australia
  17. Barreto, WolneyHospital Santa Marcelina, São Paulo, Brazil
  18. Corradini, PaoloFondazione IRCCS Instituto Nazionale dei Tumori, University of Milan, Italy
  19. Min, Chang-KiSeoul St. Mary’s Hospital, South Korea
  20. Scott, Emma C.Oregon Health & Science University, Portland, United States
  21. Chanan-Khan, Asher A.Mayo Clinic Florida, Jacksonville, United States
  22. Horvath, NoemiRoyal Adelaide Hospital, Australia
  23. Capra, MarceloInstituto do Cancer-Hospital Mae de Deus, Porto Alegre, Brazil
  24. Beksac, MeralAnkara University, Turkey
  25. Ovilla, RobertoHospital Angeles Lomas, Naucalpan de Juárez y alrededores, Mexico
  26. Jo, Jae-CheolUlsan University Hospital, South Korea
  27. 신호진Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, South Korea
  28. Sonneveld, PieterErasmus Medical Center, Rotterdam, Netherlands
  29. Soong, DavidJanssen Research & Development, LLC, United States
  30. Casneuf, TinekeJanssen Research & Development, Beerse, Belgium
저자 37명 모두 보기

초록

Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow-up is presented. After 19.4 (range: 0 to 27.7) months of median follow-up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; P <0.0001) and improved the overall response rate (83.8% versus 63.2%; P <0.0001) compared with bortezomib and dexamethasone alone. The progression-free survival benefit of daratumumab plus bortezomib and dexamethasone was most apparent in patients with 1 prior line of therapy (median: not reached versus 7.9 months; hazard ratio, 0.19; 95% confidence interval, 0.12-0.29; P <0.0001). Daratumumab plus bortezomib and dexamethasone was also superior to bortezomib and dexamethasone alone in subgroups based on prior treatment exposure (bortezomib, thalidomide, or lenalidomide), lenalidomide-refractory status, time since last therapy (=12, >12, =6, or >6 months), or cytogenetic risk. Minimal residual disease-negative rates were >2.5-fold higher with daratumumab across subgroups. The safety profile of daratumumab plus bortezomib and dexamethasone remained consistent with longer follow-up. Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse. TRIAL EGISTRATION: clinicaltrials.gov identifier: NCT02136134.

키워드

MINIMAL RESIDUAL DISEASELOW-DOSE DEXAMETHASONEOPEN-LABELINTERGROUPE FRANCOPHONEANTIBODY DARATUMUMABTARGETING CD38LENALIDOMIDEPOMALIDOMIDESURVIVALTHERAPY

식별자

Scopus EID
2-s2.0-85057954011
WoS UID
000451736600033